Skip to main content
. 2023 Apr 5;141(25):3055–3064. doi: 10.1182/blood.2022018558

Table 1.

Characteristics of included patients

Total (n = 1195) GSTT157 (n = 97) HOVON-13016 (n = 65) HOVON-8415 (n = 308) IAEA17 (n = 104) NCRI18 (n = 133) PETAL19 (n = 368) SAKK20 (n = 120)
Age (median, IQR) 62 (51-70) 61 (49-70) 63 (54-72) 65 (56-72) 57 (43-65) 61 (49-68) 61 (51-70) 59 (49-68)
 >60 y 547 (46) 47 (48) 30 (46) 100 (32) 63 (61) 63 (47) 179 (49) 65 (54)
 ≤60 y 648 (54) 50 (52) 35 (54) 208 (68) 41 (39) 70 (53) 189 (51) 55 (46)
Ann Arbor stage
 I 108 (9) 9 (9) 0 0 11 (11) 8 (6) 66 (18) 14 (12)
 II 284 (24) 20 (21) 7 (11) 55 (18) 25 (24) 51 (38) 80 (22) 42 (35)
 III 269 (23) 11 (11) 8 (12) 70 (23) 23 (22) 35 (26) 75 (20) 26 (22)
 IV 534 (45) 57 (59) 50 (77) 183 (59) 45 (43) 39 (29) 147 (40) 38 (32)
WHO performance status
 0 590 (49) 32 (33) 38 (58) 175 (57) 36 (35) 75 (56) 166 (45) 68 (57)
 1 449 (38) 35 (36) 23 (35) 94 (31) 44 (42) 44 (33) 165 (45) 44 (37)
 2 124 (10) 18 (19) 3 (5) 39 (13) 15 (14) 14 (11) 27 (7) 8 (7)
 3 30 (3) 12 (12) 1 (2) 0 7 (7) 0 10 (3) 0
 4 2 0 0 0 2 (2) 0 0 0
LDH
 ≤ Normal 478 (40) 35 (36) 16 (25) 100 (32) 54 (52) 51 (38) 154 (42) 62 (52)
 Normal 713 (60) 62 (64) 45 (69) 208 (68) 50 (48) 82 (62) 214 (58) 58 (48)
 Missing 4 4 (6)
Extranodal involvement
 ≥1 773 (65) 47 (48) 30 (46) 182 (59) 67 (64) 106 (80) 249 (68) 92 (77)
 <1 422 (35) 50 (52) 35 (54) 126 (41) 37 (36) 27 (20) 119 (32) 28 (23)
IPI low 368 (31) 26 (27) 9 (14) 51 (17) 44 (42) 52 (39) 125 (34) 61 (51)
 Low-intermediate 264 (22) 10 (10) 14 (22) 75 (24) 16 (15) 28 (31) 97 (26) 24 (20)
 High-intermediate 331 (28) 30 (31) 29 (45) 106 (34) 22 (21) 35 (26) 89 (24) 20 (17)
 High 232 (19) 31 (32) 13 (20) 76 (25) 22 (21) 18 (14) 57 (15) 15 (13)

LDH, lactate dehydrogenase.